October 10 - 12, 2018
The Ritz-Carlton, Laguna Niguel, CA
Senior Director, Business Development and Industry Relations
Keck School of Medicine of USC
Dr. Vasiliki Anest is Senior Director, Business Development and Industry Relations for the MESH (Medicine, Engineering, Sciences, and Humanities) Academy for the Keck School of Medicine of University of Southern California. In this role, Anest leads a new business development function to evaluate various levels of engagement with industry, and in collaboration with prospective partners, formulate partnering strategies that enable the convergence of disciplines that can meet an unmet need and have a greater impact on human health and disease. Prior to this role, Anest led corporate collaborations at the USC Stevens Center for Innovation, bringing an extensive background in academic-industrial relations, corporate-sponsored research, and technology commercialization management.
Anest joined USC in 2012 from Life Technologies Corporation, where she held positions as associate director of global market development, program lead of cancer and epigenetics, and associate director of global external R&D and strategic alliances, where she forged numerous strategic relationships with university, government and industry partners and led teams that span functional and divisional boundaries to identify, evaluate, and execute on alliance-based business models to drive organizational profitability.
Anest earned a Bachelor of Science in biochemistry and cell biology from the University of California, San Diego; a PhD in genetics and molecular biology from the University of North Carolina; and was a postdoctoral fellow in epigenetics with Dr. C. David Allis at The Rockefeller University.
Executive Director, Business Development
Michael joined Celgene’s Business Development team following the company’s acquisition of Abraxis BioScience in the fall of 2010. In the 3+ years Michael has been with Celgene, he has successfully completed 8 transactions and has taken the lead from a BD perspective in putting in place the company’s biologics collaborations, including deals announced with OncoMed, Adimab, AnaptysBio, Inhibrx and Sutro Biopharma. Michael joined Abraxis in early 2008, and among other accomplishments, helped establish the Abraxis commercial presence in China and helped lead the commercial launch of Abraxane in that market. Prior to joining Abraxis, Michael was involved in the tech / telecom area, working for two technology companies in southern California. Prior to these engagements, Michael was a sell-side Research Analyst at Morgan Stanley covering the wireless telecom space. Michael received his undergraduate degree from the Johns Hopkins University and his MBA from the Kellogg School of Management at Northwestern University.
Vice President of Worldwide Business Development
GVP, Corporate & Business Development
Brinda Balakrishnan, M.D., Ph.D., joined BioMarin in early 2016 and currently serves as Group Vice President, Corporate and Business Development. She leads the company’s initiatives on corporate strategy, mergers and acquisitions, and technology licensing.
Prior to BioMarin, Dr. Balakrishnan was the Co-founder and Vice President Corporate Strategy and Product Development at Vision Medicines, Inc., a start-up focused on developing treatments for rare ophthalmic diseases. In that role, she was responsible for in-licensing assets from big pharma and academia, fund-raising, and advancing a program for the treatment of Stargardt Disease. Before founding Vision Medicines, she spent two years as a consultant at McKinsey & Company in the healthcare practice serving clients across small biotech, large pharma, and provider groups on topics related to corporate strategy, corporate and business development, and operations. Prior to McKinsey, Dr. Balakrishnan was in Business Development at Genzyme.
Dr. Balakrishnan earned a Bachelor’s of Science degree from the Massachusetts Institute of Technology (M.I.T.) in Chemical Engineering and a Ph.D. from M.I.T. in Biomedical Engineering and Chemical Engineering. She also earned her M.D. from Harvard Medical School and conducted her medical training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, a Harvard hospital.
Senior Vice President
John Baldoni is Senior Vice President, In silico Drug Discovery, in GSK Pharma R&D. This department employs in silico methods to identify patient needs, explore molecular interventions to address those needs and design and conduct clinical trials to test the medical hypothesis. Using these methodologies, the conventional empirical design make test cycle will be dramatically reduced. The intent is to discover medicines at higher velocity and with greater precision compared to current approaches. John is also Co-chair of ATOM, a public private partnership to advance the methodologies used to discover oncology medicines and put them in the public domain
Prior to this, John was Senior Vice President, Platform Technology and Science (PTS), in GSK. The work of PTS spans the entire drug discovery and development process, from preclinical activities leading to clinical candidate selection through commercial launch. This accountability covered the discovery and manufacture of small molecules, biopharmaceuticals, and cell and gene therapies.
John joined GSK in 1989 and has worked in the pharmaceutical industry for 38 years. His experience spans new chemical entity design, development and commercialization, and biopharmaceutical development. In progressing to his current role, John has held various positions at GSK including Senior Vice President, Preclinical Development; Vice President, Product Development; Director, Product Development; and Assistant Director, Biopharmaceutical Formulation Development, among others. He has led several key cross-functional strategic initiatives, such as advanced manufacturing technologies and discovery modernization
John has a BS in biochemistry (1974), and MS and PhD degrees in chemistry (1980) from Penn State University.
Executive Director, Business Development & Licensing, Alliance Management
Executive Director, Corporate Alliances, Penn Center for Innovation
University of Pennsylvania
Scott Carter focuses his practice on the life sciences industry, representing life sciences companies and investors in complex transactions relating to the development and commercialization of biotechnology, pharmaceutical, diagnostic, and medical device products. He has extensive experience negotiating corporate partnership, licensing, research and development, clinical trial, manufacturing, and supply agreements. Dr. Carter also advises clients on the intellectual property aspects of mergers and acquisitions.
Dr. Carter holds a Ph.D. in chemistry from the California Institute of Technology. His research at Caltech centered on non-natural nucleosides, as well as the design, synthesis, and testing of DNA-binding molecules in the laboratory of Peter Dervan.
While at Caltech and law school, Dr. Carter was also the assistant director of the Office of Technology Transfer at Caltech. In this role, he managed the Institute’s life sciences patent portfolio, and negotiated and drafted license, research, and material transfer agreements, as well as advising Caltech entrepreneurs on new ventures.
Dr. Carter is admitted to practice in California and before the U.S. Patent and Trademark Office.
Chair, Licensing & Strategic Alliances Practice Group
Hemmie Chang is Co-chair of Foley Hoag's Life Sciences Group and Chair of its Licensing & Strategic Alliances Practice. She has closed $3 billion in deals in recent years across diverse therapeutic areas. Hemmie advised Pear Therapeutics in its Novartis collaboration (March 2018) using Pear’s first ever FDA cleared software application as digital therapeutics to treat schizophrenia and multiple sclerosis. She also represented Dicerna Pharmaceuticals (NASDQ: DRNA) in its $200+ million research collaboration with Boehringer Ingelheim announced in November 2017 to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases, initially nonalcoholic steatohepatitis (NASH). Hemmie previously advised on two of AbbVie’s four transactions publically announced in 2017: Dong-A’s $525 million Mer tyrosine kinase inhibitor deal and the Genomics Medicine Ireland collaboration for genomics research in the Irish population with WuXi NextCODE Genomics. She was also involved in Calithera’s (NASDAQ: CALA) collaboration with Incyte for CALA’s arginase inhibitor molecule in hematology and oncology and in counseling on the intellectual property aspects of Legochem’s antibody drug conjugate (ADC) research agreement with Takeda/Millennium. Clients routinely benefit from Hemmie's strategic business perspective and legal acumen from her two-plus decades of experience within the life sciences sector.
Executive Director, Business Development
Chris is part of the transactions team at Amgen and focusses on oncology with accountability for immuno-oncology deals. Chris joined Amgen as part of the Onyx acquisition in October 2013 and is based in San Francisco. Since joining the team, he has led a range of transactions focused mainly in oncology and inflammation, including Amgen’s immuno-oncology collaborations with CytomX and Kite Pharma. While at Onyx, Chris served as a co-leader of the team responsible for Onyx’s business development strategy and execution and supported Onyx’s sale process. Prior to joining Onyx, Chris was a director in Pfizer’s business development team in New York where supported deals across a broad spectrum of therapeutic areas and geographies. Earlier in his career, Chris worked as a senior consultant in CSC’s healthcare practice.
Chris earned his MBA from NYU’s Stern School of Business, and his BSE in Biomedical Engineering from The Johns Hopkins University.
VP, Global Head Search & Evaluation
Niels joined Abbvie in 2011 and has held several positions at AbbVie, including Global Commercial Leader for a late-stage oncology program, Director and Head of Commercial Business Development for Oncology, Senior Director and Head of Search and Evaluation, Oncology, and most recently Vice President and Global Head of Search and Evaluation. Transactions that Niels was involved in in his current and previous role include acquisitions (Pharmacyclics, Stemcentrx), R&D collaborations and license agreements (Argen-X, CytomX, Dong-A-ST, Harpoon, M2Gen, MD Anderson PureMHC, Turnstone, X-Chem,) and venture investments.
Prior to joining AbbVie Niels was CEO of BioPheresis, co-founder and COO of immatics biotechnologies GmbH, and a strategic management consultant for McKinsey & Company.
Niels attended University of Tuebingen in Germany and received a Master’s in Biology and a Ph.D. in Immunology.
SVP, Research, External Science & Innovation
Don joined Allergan in 2014 and leads the Research, Clinical Pharmacology, Toxicology, and ADME efforts for the organization and the External Science & Innovation efforts that partner with Business Development to evaluate and implement partnerships, licensing, and acquisitions across all therapeutic areas. With over twenty years of pharmaceutical and academia research and management experience Don has been involved in a variety of pre-clinical drug discovery and Ph1/Ph2 clinical research areas and environments, including the entry of more than 25 compounds into development across therapeutic areas. Previous roles included heading the Emerging Innovations Unit at AstraZeneca, the Indications Discovery Units at Pfizer, the CNS Discovery organization at Pharmacia.
Managing Partner & CEO
Back Bay Life Science Advisors
Senior Vice President
Back Bay Life Science Advisors
Founder & CEO
Impact Biosciences, a Celgene subsidiary
John Hood was the Founder and Chief Executive Officer of Impact Biomedicines, a company that was acquired by Celgene in 2018 and is now a wholly owned subsidiary of Celgene. Prior to founding Impact, Dr. Hood was the Co-Founder and Chief Scientific Officer of Samumed, a pharmaceutical company focused on advancing regenerative medicine and oncology therapies. Prior to that, Dr. Hood was Director of Research and Co-inventor of fedratinib at TargeGen, Inc., (subsequently acquired by Sanofi SA), where he led a team identifying small molecule kinase inhibitors for the treatment of eye diseases and cancer. He is an inventor on 100+ patents and author on 50+ scientific articles. Dr. Hood obtained a Ph.D. in medical physiology and B.S. in biochemistry from Texas A&M University.
VP, Head of Business Development
VP, Business Development
VP, Venture Capital
Alliance Management & New Project Planning Leader
Lauren Kaskiel, leads Alliance Management for Spark Therapeutics, a biotech company challenging the inevitability of genetic disease by discovering, developing, and delivering treatments in ways unimaginable-until now. Lauren is responsible for managing alliances for in and out-licensed programs and academic collaborations and also leads new product planning assessments for Spark’s R&D programs.
Prior to joining the Corporate Strategy and Public Affairs team at Spark in June of 2015, Lauren was with GlaxoSmithKline (GSK) for 14 years, starting her career in R&D after completing her B.S. in Biotechnology from Penn State University. After completing an M.B.A. from Drexel University in 2007, Lauren supported Oncology Business Operations before becoming an Alliance Director within Worldwide Business Development, managing a portfolio of GSK’s alliances with biotech, diagnostic and venture partners.
Lauren has her Certificate of Achievement in Alliance Management (CA-AM) through the Association of Strategic Alliance Professionals (ASAP) and is an active member of the Board for the ASAP Tri-State Chapter. Additionally, Lauren is a guest lecturer at Penn State University’s Science 402 course and has occasionally been a speaker on scientific career-related topics at both Penn State and Drexel University.
Current investments include Cidara (CDTX), Eiger Biopharmaceuticals, Lycera, Ocera (OCRX), Paratek (PRTK), and WellTok.
Previous investments include Labrys Biologics (acquired by Teva), Alt12 (acquired by Honest Company), Trius Therapeutics (TSRX; acquired by Cubist), CNS Therapeutics (acquired by Covidien), NovaCardia (acquired by Merck), and Aspreva (ASPV; acquired by Galenica)
Prior to InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.
Nina received a B.A. in human biology from Stanford University (1997).
She serves on the California Leadership Council for the Nature Conservancy and has been nominated to join the board of the California Family Health Council.
SVP, Strategy Consulting
Back Bay Life Science Advisors
Lilly Asia Ventures
Dr. Hongbo Lu is a partner at Lilly Asia Ventures, a healthcare-focused global investment firm with over USD$1.2 billion estimated AUM. Previously, Dr. Lu was with OrbiMed Advisors, serving as its Managing Director in Asia. She has over 15 years of investment and operational experience in the healthcare industry, including her tenures at OrbiMed, Piper Jaffray & Co. and life science start-up Zyomyx. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honors from Tsinghua University in China.
Executive Director, Business Development
Angèle Maki is a business development executive with fourteen years of deal-making experience spanning small biotech and big pharma. She is currently an Executive Director of Business Development & Licensing at Merck’s West Coast Innovation Hub where she leads Search & Evaluation in oncology, immunology, and virology. Prior to Merck, Angèle was an Associate Director in Genentech’s Partnering group where she was responsible for developing and executing technology licensing strategies for human genetics, antibody engineering, small molecule drug discovery, biomarkers/diagnostics, and other research technologies across therapeutic areas. While she was at Genentech, Angèle led the deals with 23andMe, OMT, and Human Longevity among others. Prior to Genentech, Angèle was a Director in BMS’ Strategic Transactions Group where she was responsible for in-licensing and out-licensing of technologies related to discovery and development of biologics. Prior to BMS, Angèle was in Business Development at Medarex, Inc., a biopharmaceutical company focused on the discovery and development of fully-human antibody therapeutics, primarily in the nascent field of cancer immunology, which was acquired by BMS in 2009. During her business development and licensing tenure, she has successfully negotiated numerous in- and out-licensing transactions, from early-stage research technologies to clinical-stage assets. Angèle received a Ph.D. in biological chemistry from Stanford University and completed postdoctoral work in molecular biology at the Scripps Research Institute in La Jolla. She completed her B.Sc. in chemistry at the University of Winnipeg, in Canada.
Ari Nowacek, M.D, Ph.D. is a Principal with ARCH Venture Partners, joining the company as an Analyst in March 2015. Dr. Nowacek focuses on identifying and evaluating new life sciences technologies and also provides operating assistance to early-stage portfolio companies. Dr. Nowacek is a physician-scientist by training with over 20 peer-reviewed publications and greater than 400 citations in the areas of neuroscience, virology, and antiretroviral therapeutic development. His research has led to 3 issued and 2 pending patents for therapeutic and R&D applications.
He holds a B.S. in Biology and a B.S. in Psychology from the University of Indiana-Bloomington where he graduated Magna Cum Laude and was elected to Phi Beta Kappa. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an M.B.A. from the University of Nebraska-Omaha. He subsequently completed a medical residency in pathology and post-doctoral research at The University of Chicago and Massachusetts General Hospital.
SVP, Research Business Development
City of Hope
California Life Sciences Association
SVP, Industry Relations
Kent currently serves as the Senior Vice President, Industry Relations for OptumRx with responsibility for formulary and procurement contracting for all books of business on behalf of internal and external clients of United Health Group. OptumRx is the pharmacy benefit management division of Optum servicing over 66 million members and processing over 1 billion pharmacy claims which represent over $80 billion in drug spend. He has more than 25 years of experience with the pharmaceutical industry, focusing primarily on payer, channel and patient services strategies. Prior to OptumRx, Kent was a Principal Consultant with Blue Fin Group, served as the Vice President of Managed Markets at Acorda Therapeutics, and held various positions of increasing responsibility within Sales and Managed Markets at Schering Plough and Merck. His career experience includes business development, health economics/outcomes research, building and leading market access teams, developing and implementing payer access and channel strategies, and launching patient services programs. Kent has a Bachelor of Science in Business Management from Indiana University, and an MBA from Emory University’s Goizueta School of Business.
US Head, Business Development & Licensing and Specialty Pharma
VP, Head of Business Development, North America
Kristen B. Slaoui, PhD is Vice President and Head of Business Development for GlaxoSmithKline (GSK) North America. She has spent nearly eighteen years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. Since joining GSK’s Business Development teams in 2006, she has held various roles of increasing seniority and has executed more than $20 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009 and participating in the $20+ billion three-part transaction with Novartis in 2015, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces. Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.
Head, JLABS Bay Area
Johnson & Johnson Innovation
Lesley is the Head of JLABS California including JLABS @ SSF, JLABS @ QB3 and our flagship JLABS San Diego. In this role, Lesley is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming and P&L. In this role, she catalyzes and support the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device and consumer healthcare sectors.
Prior to JLABS, Lesley was Head of Transactions at Johnson & Johnson Innovation in Menlo Park. She has been working in corporate and business development roles for the last 17 years for companies that are both technology platform and therapeutics focused. Her most recent executive positions have been with BioTime, a publicly traded stem cell technology and therapeutic company, and Sutro Biopharma, a platform technology company working in cell-free protein synthesis. Prior to Sutro, Lesley served in BD positions for a number of biotech companies in the U.S. and Europe.
Lesley received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School’s Department of Biochemistry and Molecular Pharmacology.
Head, West Coast Innovation Hub & AVP, BD&L
Director, SBIR Development Center
National Cancer Institute
Michael Weingarten is the Director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute in Bethesda, MD. In this role, Mr. Weingarten leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of $135M in grants and contracts annually. The SBIR & STTR programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Mr. Weingarten has implemented a set of key initiatives for optimizing the performance of the NCI SBIR Program at the NIH. These include the establishment of a new model at the NCI for managing the program - the SBIR Development Center. Under Mr. Weingarten's leadership, the NCI SBIR Development Center has launched a range of new initiatives to facilitate the success of small businesses developing cancer-related technologies. Recent initiatives include the launch of the NIH I-Corps™ pilot program in which teams of budding entrepreneurs engage in a hypothesis-driven approach to validate their proposed business models by conducting over 100 interviews with potential customers. Companies adjust their strategies based on direct customer feedback and analyze the information they collect to determine if there is a product/market fit. Other NCI SBIR initiatives introduced under Mr. Weingarten's leadership include the NCI SBIR Investor Forums, the NCI SBIR Phase II Bridge Award, and the workshop titled Federal Resources to Accelerate Commercialization (FRAC). Thus far, NCI SBIR has held three investor forums that in total have facilitated the closing of investment deals with NCI-funded SBIR companies valued at over $300M. The NCI SBIR Phase II Bridge Award, which was launched in 2009, incentivizes partnerships between NIH's SBIR Phase II awardees and third-party investors and/or strategic partners to help small businesses bridge the funding gap between the end of their SBIR Phase II awards and the next round of financing needed to advance a promising cancer therapy or imaging technology.
SVP, Business Development & Alliance Management
Mr. Whalen has more than 20 years of experience in the healthcare industry leading and supporting transactions involving acquisitions, co-promotions, out licenses and strategic alliances. Mr. Whalen joined Horizon Pharma in April of 2010 and has led or supported Horizon’s acquisitions since that time helping to grow Horizon from a pre-commercial company with no sales to over $750 million in net sales in 2015. Recent transactions include Horizon’s acquisitions of Crealta Holdings LLC for $510 million and PENNSAID® 2% for $45 million. He also led the out licensing of LODOTRA® and DUEXIS® ex-U.S. and has supported Horizon’s IPO and other fund raising activities. Prior to Horizon, he was at Baxter Healthcare where he led and supported a number of transactions as part of Baxter’s Medication Delivery business. Mr. Whalen worked at Searle prior to Baxter where his experience included various finance roles supporting business development, European operations, U.S. marketing, and R&D. He earned a MBA from the University of Illinois and bachelor’s degree from the University of Notre Dame.
VP, Global Business Development
Dr. York is Vice President, Global Business Development, Daiichi Sankyo Group and leads the Oncology Transactions team responsible for identification, evaluation and negotiation of all Oncology BD and Licensing opportunities. Dr. York received his B.A. in Biology from the University of Pennsylvania, his M.D. from Boston University and his MBA from the Stern School of New York University. He completed residency training in Internal Medicine and Emergency Medicine at the Albert Einstein College of Medicine. He began his healthcare career in Emergency Medicine as a Director of Emergency Services for several hospitals in the N.Y Metro area. Previously he was a Managing Director at Foundation Ventures, a boutique Life Sciences investment and merchant banking firm focused on the venture capital market. Over the past decade at Daiichi Sankyo his responsibilities have included New Product Planning and US Business Development where he and his team supported the Company’s Oncology, Pain and Immunology portfolios. In his current role he is a member of the Senior Licensing Committee and works directly with Daiichi Sankyo’s Cancer Enterprise and global senior management on acquisition, licensing, and research and development collaboration projects. Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases and other rare diseases.
CEO & Co-Founder
Alice Zhang is CEO of Verge Genomics, a next-generation therapeutics company using machine learning and human genomics to accelerate drug discovery for neurodegenerative diseases. She co-founded the company in 2015 with the vision that convergent advances in computation and neurobiology have created an unprecedented opportunity to rapidly unlock multiple breakthrough therapies at scale across human disease. The Verge team is 14 people uniquely combining top talent in computation and drug development, including 12 PhDs in machine learning, applied math, and neuroscience, two former professors, and two pharma veterans responsible for commercial successes such as Abilify.
Zhang has received numerous awards for her work as a scientist and entrepreneur, including the Featured Honoree in Forbes' 30 under 30 2017 and the prestigious Paul & Daisy Soros Fellowship for New Americans. Prior to starting Verge, Zhang has been at the forefront of systems biology research for over a decade at the National Institutes of Health, the Lewis-Sigler Institute for Integrative Genomics at Princeton University, and UCLA. She graduated from Princeton University magna cum laude with high honors in Molecular Biology and subsequently trained for five years in the UCLA-Caltech MD/Ph.D. program investigating gene networks involved in neuro-regeneration.
Biotech Spotlight Presenters
Dr. Buelow is founder and CEO of Teneobio. He has worked in biotechnology for thirty years and is a serial entrepreneur. In 2007 Dr. Buelow founded OMT, which was acquired by Ligand in 2015. He is also a founder of THP, Inc. (2003), which was acquired by Roche in March 2007. Between 1993 and 2003, Dr. Buelow was senior vice president of Research and Development at SangStat Medical Corporation. Dr. Buelow has published more than 100 manuscripts and is an inventor on more than 25 patents.
Chief Business Officer
Brian Fenton has served as Chief Business Officer at Translate Bio since 2015. With more than 25 years of experience in the biotechnology industry and broad transaction experience in business development and alliance management, Brian joined Translate Bio from Shire Pharmaceuticals, where he most recently served as head of business development, neuroscience, supporting the Commercial Business Unit. In this role, he was also responsible for managing Shire’s portfolio investments through its former Strategic Investments Group. Brian also spent several years in Shire’s Rare Diseases Business Development group, where he successfully led and executed a number of strategic transactions for the company. Prior to Shire, Brian spent over 11 years in various roles in business development and alliance management at Idenix Pharmaceuticals, Codexis and Abbott Laboratories. He has been a co-chair for over 20 years with MassBio, serving on several committees, and most recently served on the organization’s Forum Advisory Board. Brian has an undergraduate degree in biochemistry from the University of Massachusetts/Amherst, an MS in chemical engineering from the University of Virginia and an MBA from the Worcester Polytechnic Institute.
President & CEO
Dr. Schellenberger has over 20 years of industry experience in protein engineering and drug discovery. Prior to co-founding Amunix he served as head of Genencor’s protein engineering department.
Dr. Schellenberger received his Ph.D. from Leipzig University, where he studied protease catalyzed peptide synthesis. After postdoctoral studies at the Institute for Protein Research in Pushchino (Russia), he moved to the University of Göttingen where he developed a novel method for the production of peptides from recombinant peptide-multimers. After a postdoctoral fellowship with Bill Rutter at the University of California, San Francisco, Dr. Schellenberger joined Genencor in 1994. Dr. Schellenberger is the author of over 40 scientific papers and an inventor on more than 70 issued and pending patent applications. He is also the recipient of the Karl Lohman award of the German Society of Biochemists.
Chairman, Board of Directors
Anil Gulati, MD, PhD is Professor and Associate Dean at the Midwestern University, Illinois. He is a consultant to Advocate Lutheran General Children’s Hospital and is Adjunct Professor of Bio-engineering and Biopharmaceutical Sciences at University of Illinois at Chicago. Dr. Gulati is the Scientific Reviewer, United States Defense Medical Research and Development Program, Combat Casualty Care Research Program 2016 and 2017. He is recipient of Outstanding Faculty Award 2017, Paul R Dawson Biotechnology Award 2014 and Littlejohn Award 2014. Dr. Gulati is a United States Fulbright Scholar 2008-2009 and winner of International Ranbaxy Research Award 2007. He has ~300 peer reviewed publications and guided researches of more than 100 graduate students, medical residents and research fellows. He has 5,006 citations, h-index of 39, i10-index of 137, research gate score of 46.34. He has 42 issued patents of which 20 has been issued by the US patent office, and rest by patent offices in Europe, India, China, Japan, Australia and Canada. Some of the discoveries related to endothelin made by him are undergoing clinical phase II trials in the United States and clinical phase III trials in India. Dr. Gulati is founder and chairman of Pharmazz, Inc. and Pharmazz India Private Limited which is engaged in developing his inventions for critical care medicine, resuscitation of shock, stroke and complication of diabetes. He is an elected Fellow of American College of Clinical Pharmacology and was Co-Chair of the ET-14: World Endothelin Conference 2015, Savannah, Georgia.
Head of Commercial Operations
Mr. Passmore has over 20 years of technical and operations experience in discovery-stage organizations developing first-in-class biotherapeutics. Mr. Passmore initiated his scientific career in the mid-1990’s with Anergen, a biotechnology company that pioneered immuno-therapies against autoreactive T-Cells. Mr. Passmore later joined Dynavax Technologies to work on the early development of CpG immuno-stimulants as vaccine adjuvants. In 2001, Mr. Passmore signed on with immuno-oncology leader Medarex where he established, and built over time, a state-of-the-art analytical lab for characterization of therapeutic antibodies to support discovery operations. During his tenure at Medarex, Mr. Passmore was an integral part of the team that discovered ipilimumab (Yervoy®) and nivolumab (Opdivo®). It was at this time that Mr. Passmore obtained his MBA through an Executive program at Pepperdine University. Mr. Passmore went to Bristol-Myers Squibb in 2009 as part of the BMS acquisition of Medarex. At BMS, Mr. Passmore led a team of scientists that identified clinical candidates for multiple programs in immuno-oncology and targeted cancer therapies. Drawing on his industry experience and business training, Mr. Passmore founded a consulting practice in 2017 to provide technical and commercial services to biotechnology companies; including at immunomics leader HealthTell, where he was instrumental in the formation of RubrYc Therapeutics in March 2018. Mr. Passmore currently heads up the commercial team at RubrYc and is responsible for the company’s business development, commercial strategy, and marketing communications.
Senior Vice President Business Development & Licensing
Hookipa Pharma Inc.
Dr. Torsten Mummenbrauer is Senior VP Business Development & Licensing at Hookipa. With almost 20 years of business development experience in the life science industry and 10 years in vaccines, Torsten is able to astutely lead the business development team. Before joining Hookipa, Torsten was Senior Director Business Development at MorphoSys AG, Munich, Germany. Previously, Torsten worked for more than 10 years at GlaxoSmithKline Vaccines where he was the Global Head of the Vaccines Transactions Team with responsibility for all vaccine business development activities ranging from collaborations, option and licensing contracts to mergers & acquisitions. During the 2009 influenza pandemic he led all of GSK’s BD related influenza pandemic preparedness activities. Prior to GSK, he was Patent & Licensing Manager at the Technology Transfer office of the Max-Planck-Society, Munich, Germany. Torsten holds a PhD in tumor virology from the Heinrich-Pette Institute, Leibniz-Institute for Experimental Virology in Hamburg, Germany.
Alexis Peyroles has more than 20 years of management and financial control experience, having served in related positions, internationally. He joined Sanofi-Aventis in 1996 as Financial Controller in Japan before becoming Head of Financial Control for the Baltic States. He was subsequently named Head of activities for Business Development in Eastern Europe. In 2005, Alexis joined the Guerbet group (a leader in the field of contrast products, especially in medical imaging) as Financial Control Manager and in 2009, became Chief Executive Officer for Latin America, based in Brazil. As soon as 2013, Alexis Peyroles has been involved in OSE Pharma as Chief Financial Officer and in charge of Business Development. From May 2016 (date of the merger of OSE Pharma with Effimune) to April 2018, he served as Chief Operating Officer of OSE Immunotherapeutics, in charge of Finance, Business Development and Operations. Alexis Peyroles is graduated from EDHEC Business School and holds an Executive MBA from Imperial College in London.
President & CEO
Provid Pharmaceuticals Inc.
Chief Executive Officer
Bill has a career filled with leading US and Global Oncology drug development and commercial teams that launched three market leading oncology brands in the US. Bill has held senior management and executive roles with leading oncology companies including AstraZeneca, Adria Laboratories (now Pfizer), and Ascalon International.
Martin has a background in molecular biology and approximately 10 years of corporate experience in the biotech industry. Prior to joining OncoImmune, he was Vice President of Business Strategy at Amplimmune, Inc. where his responsibilities included overseeing all project management and operation activities. Consequently he is experienced with all aspects of the drug development process, including research, development, GMP manufacturing, regulatory and clinical trials. Martin has a proven track record developing pre-clinical assets through IND submission and into early clinical stage development. In addition, Martin has helped secure millions of dollars in government grants and formed licensing partnerships with industry partners for each stage assets. Martin was an integral member of the business development team that lead to its successful sale to MedImmune for up to $500 million in 2013.
Chief Business Officer
Iman Daryaei, PhD, is a Research & Development scientist at NuvOx Pharma
where he applies his knowledge and skills to develop new targeted ultrasound
contrast agents for early detection of cancer. Dr. Daryaei graduated from the
University of Arizona with his doctorate in Biological Chemistry and a minor in
Entrepreneurship. His graduate research focused on molecular imaging for early
detection of cancer. Prior to his doctorate, Dr. Daryaei also obtained two MSc
degrees in Medicinal Chemistry and Organic Chemistry.
Sunil Gangadharan, PhD joined imec in early 2017 and is responsible for cultivating strategic alliances as well as developing co-operative R &D programs with Industrial Partners for them to access and leverage imec’s unique capabilities and solutions in advanced “More-than-Moore” semiconductor technology.
Prior to imec, he managed industry-academic collaborations and out-licensing of technologies at Partners Healthcare Innovation, Boston.
Sunil earned his PhD in Biochemistry from the Indian Institute of Science and held post-doctoral fellowships in Genetics and Genomics at Johns Hopkins Medical School and the National Institutes of Health in Bethesda, USA.
CSO, CBDO & Founder
Gail K. Naughton, Ph.D., has spent nearly 30 years extensively researching the tissue engineering process, holds over 105 U.S. and foreign patents, and has founded two regenerative medicine companies. Her current venture, Histogen, is focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions. She currently serves as the Company’s CSO and CBDO, and is the inventor of its core technology. In addition, Dr. Naughton served as the Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. Prior to that, she spent more than 15 years at Advanced Tissue Sciences, where she was the company’s co-founder and co-inventor of its core technology. During her tenure there, Dr. Naughton held a variety of key management positions, including president, chief operating officer, chief scientific officer and principal scientist. While serving as an officer and director of the Company, Dr. Naughton oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four products from concept through FDA approval and market launch. These products include a skin replacement for severe burns (TransCyte),a living dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm) and SkinMedica’s TNS product for skin care. At Histogen Dr. Naughton developed a new skin care product which also contains human growth factors, ReGenica, which was recently acquired by Allergan.
Dr. Naughton has been extensively published and a frequent speaker in the field of tissue engineering. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton sits on several Boards including the CCRM, the Ackerman foundation, and Cytori Therapeutics.
Business Development and Strategy Lead
Kevin Heyries holds a PhD in biochemistry (Uni. of Lyon, France) where his doctoral work focused on the development of miniaturized technology using microfluidics for antibody analysis. During his postdoctoral work (Uni. of British Columbia), he developed high throughput microfluidics systems for digital PCR and single-cell genomics. Dr. Heyries was instrumental in the development of AbCellera’s technology, where he also led several antibody discovery programs and is now leading business development and strategy.